Table 2 The clinicopathologic features, molecular findings, and treatment/follow-up data for 22 RAS-amplified metastatic colorectal carcinomas.
Case | Age (years) | Sex | History of IBD | Primary colonic origin | Histologic subtype | Histologic grade | RAS gene amplification (CN) | Other genomic alterationsa | MMR protein status | Anti-EGFR treatment | Follow-up (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 49 | M | Yes (UC) | Rectum | Conventional | Moderate | KRAS (19) | Preserved | Yes (panitumumab)b | AWD (18) | |
2 | 45 | M | Yes (UC) | Rectum | Conventional | Moderate | KRAS (17) | Preserved | No | AWD (27) | |
3 | 73 | M | Yes (UC) | Sigmoid colon | Conventional | Moderate | KRAS (10) | Preserved | Yes (panitumumab)b | AWD (57) | |
4 | 63 | M | Yes (UC) | Sigmoid colon | Conventional | Moderate | KRAS (6) | Preserved | Yes (panitumumab)b | AWD (30) | |
5 | 38 | F | Yes (Crohn’s) | Cecum | Signet-ring cell | Poor | KRAS (13) | Preserved | No | DOD (5) | |
6 | 54 | F | Yes (UC) | Sigmoid colon | Conventional | Moderate | KRAS (7) | Preserved | N/A | N/A | |
7 | 59 | M | No | Cecum | Micropapillary | Moderate | KRAS (14) | Preserved | No | DOD (6) | |
8 | 61 | M | No | Cecum | Mucinous | Moderate | KRAS (8) | BRAF p.V600E | Preserved | No | DOD (31) |
9 | 60 | F | No | Ascending colon | Mucinous | Moderate | KRAS (8) | Preserved | Yes (panitumumab)b | DOD (23) | |
10 | 26 | M | No | Sigmoid | Conventional | Poor | KRAS (7) | Preserved | No | AWD (15) | |
11 | 78 | M | No | Rectum | Conventional | Moderate | KRAS (6) | KRAS p.G12V | Preserved | No | DOD (7) |
12 | 74 | M | No | Rectum | Conventional | Moderate | KRAS (7) | KRAS p.G12R | Preserved | No | DOD (21) |
13 | 41 | M | Yes (Crohn’s) | Rectum | Conventional | Poor | KRAS (12) | KRAS p.G12D | Preserved | No | DOD (2) |
14 | 57 | M | Yes (Crohn’s) | Rectum | Conventional | Moderate | KRAS (6) | KRAS p.A146T | Preserved | No | DOD (8) |
15 | 53 | M | Yes (Crohn’s) | Rectum | Conventional | Moderate | KRAS (6) | KRAS p.G12D | Preserved | No | DOD (15) |
16 | 57 | M | No | Rectum | Conventional | Moderate | NRAS (16) | Preserved | Yes (panitumumab)c | AWD (10) | |
17 | 52 | M | No | Rectum | Conventional | Moderate | NRAS (14) | Preserved | N/A | N/A | |
18 | 51 | F | No | Rectum | Conventional | Poor | NRAS (8) | NRAS p.G12D | Preserved | No | DOD (156) |
19 | 72 | M | No | Cecum | Mucinous | Moderate | NRAS (7) | KRAS p.G12R | Preserved | No | DOD (11) |
20 | 66 | M | No | Cecum | Mucinous | Moderate | NRAS (6) | KRAS p.G12S | Preserved | No | DOD (11) |
21 | 67 | F | No | Cecum | Mucinous | Poor | HRAS (21) | BRAF p.V600E | MLH1/PMS2-deficient | No | DOD (31) |
22 | 79 | F | No | Cecum | Mucinous | Poor | HRAS (19) | BRAF p.V600E | MLH1/PMS2-deficient | No | DOD (20) |
